Literature DB >> 11278324

Dopamine D2 receptor dimer formation: evidence from ligand binding.

D Armstrong1, P G Strange.   

Abstract

We have examined the binding of two radioligands ([(3)H]spiperone and [(3)H]raclopride) to D(2) dopamine receptors expressed in Chinese hamster ovary cells. In saturation binding experiments in the presence of sodium ions, both radioligands labeled a similar number of sites, whereas in the absence of sodium ions [(3)H]raclopride labeled about half the number of sites labeled by [(3)H]spiperone. In competition experiments in the absence of sodium ions, however, raclopride was able to inhibit [(3)H]spiperone binding fully. In saturation analyses with [(3)H]spiperone in the absence of sodium ions raclopride exerted noncompetitive effects, decreasing the number of sites labeled by the radioligand. These data are interpreted in terms of a model where the receptor exists as a dimer, and in the absence of sodium ions, raclopride exerts negative cooperativity across the dimer both for its own binding and the binding of spiperone. A model of the receptor has been produced that provides a good description of the experimental phenomena described here.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11278324     DOI: 10.1074/jbc.M006936200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  35 in total

1.  Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists.

Authors:  José L Moreno; Terrell Holloway; Laura Albizu; Stuart C Sealfon; Javier González-Maeso
Journal:  Neurosci Lett       Date:  2011-01-27       Impact factor: 3.046

2.  Functional homomers and heteromers of dopamine D2L and D3 receptors co-exist at the cell surface.

Authors:  Chantevy Pou; Clotilde Mannoury la Cour; Leigh A Stoddart; Mark J Millan; Graeme Milligan
Journal:  J Biol Chem       Date:  2012-01-30       Impact factor: 5.157

3.  Trans-activation between 7TM domains: implication in heterodimeric GABAB receptor activation.

Authors:  Carine Monnier; Haijun Tu; Emmanuel Bourrier; Claire Vol; Laurent Lamarque; Eric Trinquet; Jean-Philippe Pin; Philippe Rondard
Journal:  EMBO J       Date:  2010-11-09       Impact factor: 11.598

Review 4.  Allostery at G protein-coupled receptor homo- and heteromers: uncharted pharmacological landscapes.

Authors:  Nicola J Smith; Graeme Milligan
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

Review 5.  Oligomerization of G protein-coupled receptors: past, present, and future.

Authors:  Paul S-H Park; Slawomir Filipek; James W Wells; Krzysztof Palczewski
Journal:  Biochemistry       Date:  2004-12-21       Impact factor: 3.162

Review 6.  Receptor-receptor interactions, receptor mosaics, and basic principles of molecular network organization: possible implications for drug development.

Authors:  Luigi F Agnati; Alexander O Tarakanov; Sergi Ferré; Kjell Fuxe; Diego Guidolin
Journal:  J Mol Neurosci       Date:  2005       Impact factor: 3.444

Review 7.  Oligomers of D2 dopamine receptors: evidence from ligand binding.

Authors:  Philip G Strange
Journal:  J Mol Neurosci       Date:  2005       Impact factor: 3.444

Review 8.  Entropy and oligomerization in GPCRs.

Authors:  Rajkumar P Thummer; Matthew P Campbell; Mark K Dean; Marie J Frusher; Paul D Scott; Christopher A Reynolds
Journal:  J Mol Neurosci       Date:  2005       Impact factor: 3.444

Review 9.  Intramembrane receptor-receptor interactions: a novel principle in molecular medicine.

Authors:  K Fuxe; M Canals; M Torvinen; D Marcellino; A Terasmaa; S Genedani; G Leo; D Guidolin; Z Diaz-Cabiale; A Rivera; L Lundstrom; U Langel; J Narvaez; S Tanganelli; C Lluis; S Ferré; A Woods; R Franco; L F Agnati
Journal:  J Neural Transm (Vienna)       Date:  2006-10-27       Impact factor: 3.575

Review 10.  On the fitting of binding data when receptor dimerization is suspected.

Authors:  J Giraldo
Journal:  Br J Pharmacol       Date:  2008-06-09       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.